Vijaya Diagnostic Centre Limited enters its Q1 FY27 results following a year of record-breaking expansion and strong operating leverage. Investors will be focused on whether the company can sustain its 40% EBITDA margin threshold while navigating a seasonally softer quarter and a significant leadership transition in its finance and technology departments.
| Results date | August 06, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 219.4 Cr |
| Previous quarter PAT | Rs. 47.9 Cr |
| Previous quarter EBITDA margin | 43.5% |
| Market cap | Rs. 13847.01 Cr |
| CMP | Rs. 1344.4 |
The board meeting is scheduled for August 6, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
The earnings conference call is scheduled for August 7, 2026, at 10:30 AM IST with MD & CEO Suprita Reddy and CFO Narasimha Raju.
Revenue for Q1 FY27 is expected to show a seasonal decline from the Q4 FY26 peak of Rs. 219.4 Cr, though it should remain healthy on a year-over-year basis supported by network additions and vector-borne disease trends. Management's H1 FY27 plan includes the addition of 1 hub and 10 spokes, and the performance of these new centres will be a key indicator of the company's ability to maintain its growth trajectory. While EBITDA margins may compress from the 43.5% reported in Q4 FY26 due to lower fixed-cost absorption and new hub set-up costs, the company is expected to remain above its 40% guidance floor given the favourable 11.6% material-cost-to-revenue ratio and strong B2C revenue share. The upcoming call will likely address the impact of the leadership transition, with Narasimha Raju K.A. presiding over his first results as the newly appointed CFO.
Performance vs Guidance Tracking: Tracking progress against FY27 strategic targets.
Strategic execution and capex updates: Monitoring infrastructure projects and network densification.
Risks and headwinds to monitor: Management-flagged operational and leadership transitions.
Management attributes their higher revenue per patient to a 92% B2C business model and a 60:40 radiology-pathology mix. They focus on volume-driven growth rather than aggressive price increases.
New hub openings typically incur an initial operating expense drag, but management noted this impact was only 0.8% in Q4 FY26, significantly better than the projected 2–2.5%. They remain confident in maintaining margins above 40% despite ongoing expansion.
Management remains open to inorganic opportunities if the assets align with their B2C-driven value system. They recently approved the acquisition of MRI, EEG, and NCV services from a subsidiary for Rs. 4.20 Cr.
The company has set a target for 4–5 new hubs and 10–12 new spokes in FY27. For H1 FY27, they planned to commission 1 hub and 10 spokes, with progress updates expected during the upcoming earnings call.
Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings
Login Now